Table 1 Patient clinical characteristics
Characteristic | Total(%) n = 93 | DR n = 22 | No-DR n = 71 | P value |
|---|---|---|---|---|
Age* | 63±13 | 60±13 | 64±12 | 0.243 |
Sex | Â | Â | Â | Â |
 Female | 43 (46.2) | 15 (68.2) | 28 (39.4) | 0.018 |
 Male | 50 (53.8) | 7 (31.8) | 43 (60.6) |  |
ECOG ps | Â | Â | Â | Â |
1 | 20 (21.5) | 3 (13.6) | 17 (24.0) | 0.566 |
2 | 52 (55.9) | 14 (63.7) | 38 (53.5) | Â |
3 | 21 (22.6) | 5 (22.7) | 16 (22.5) | Â |
No. of prior systemic therapies | Â | Â | Â | Â |
 < 3 | 72 (77.4) | 15 (68.2) | 53 (74.6) | 0.550 |
 ≥ 3 | 21 (22.6) | 7 (31.8) | 18 (25.4) |  |
Metastatic organs involved | Â | Â | Â | Â |
 < 3 | 68 (73.1) | 16 (72.7) | 56 (78.9) | 0.547 |
 ≥ 3 | 25 (26.9) | 6 (27.3) | 15 (21.1) |  |
PD-L1 status | Â | Â | Â | 0.260 |
 < 1 | 15 (16.1) | 5 (22.7) | 10 (14.1) |  |
 ≥ 1 | 19 (20.4) | 2 (9.1) | 17 (23.9) |  |
 Unknown | 59 (63.5) | 15 (68.2) | 44 (62.0) |  |
Primary cancer sites | Â | Â | Â | Â 0.541 |
 Lung | 18 (19.4) | 4 (18.2) | 14 (19.7) |  |
 Colorectum | 16 (17.2) | 3 (13.7) | 13 (18.3) |  |
 Breast | 4 (4.3) | 1 (4.5) | 3 (4.2) |  |
 Gastro | 7 (7.5) | 0 (0.0) | 7 (9.9) |  |
 Cervix | 7 (7.5) | 4 (18.2) | 3 (4.2) |  |
 Esophagus | 10 (10.8) | 2 (9.1) | 8 (11.3) |  |
 Ovary | 5 (5.4) | 2 (9.1) | 3 (4.2) |  |
 Head and neck | 6 (6.5) | 1 (4.5) | 5 (7.0) |  |
 Liver | 6 (6.5) | 1 (4.5) | 5 (7.0) |  |
 Pancreas | 6 (6.5) | 1 (4.5) | 5 (7.0) |  |
 Others | 8 (8.4) | 3 (13.7) | 5 (7.0) |  |
No. of irradiated sites | Â | Â | Â | Â |
 1 | 38 (40.9) | 6 (27.3) | 32 (45.1) | 0.332 |
 2 | 38 (40.9) | 11 (50.0) | 27 (38.0) |  |
 ≥ 3 | 17 (18.2) | 5 (22.7) | 12 (16.9) |  |
Tumor response by lesion to lesion | Â | Â | Â | Â |
 Uniform response | 27 (29.0) |  |  |  |
 Dissociated response | 22 (23.7) |  |  |  |
 Only stable lesions | 20 (21.5) |  |  |  |
 Uniform progression | 24 (25.8) |  |  |  |